tirzepatide for non diabetic patients Injections Medical Weight Loss in Fayetteville NC Tirzepatide leads to significant weight
Description
Wegovy (semaglutide) is a GLP-1 receptor agonist licensed for weight management, whilst Forxiga (dapagliflozin) is an SGLT2 inhibitor primarily used for type 2 diabetes, heart failure, and chronic kidney disease
Most patients experience appetite reduction within weeks, but significant weight loss typically begins at Month 2 or 3
A patient who lost weight but developed fatigue, constipation, under-eating, or muscle weakness may need a different strategy than a patient who lost weight steadily, maintained strength, and improved lab markers
Furthermore, weight loss with tirzepatide can lead to increased energy and mobility, making activity more enjoyable
Compounded GLP-1: regulatory context in 2026
